MEDP vs PTCT Stock Comparison
MEDP currently leads PTCT in this stock comparison, with AIQ scores of 57 vs 54. The clearest difference is momentum, while PTCT has the stronger value profile.
What is the main difference between MEDP and PTCT?
MEDP leads the current stock comparison as Medpace Holdings, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Medpace Holdings, Inc. vs PTC Therapeutics, Inc.
MEDP leads
MEDP leads by 3 AIQ points, primarily on Momentum and Risk Resilience, but the lead has narrowed from 9 points over 30 sessions. Wall Street currently favors PTCT on target upside.
Fragile: 3 of 6 evidence groups support MEDP, its lead is narrowing, and its signal state is cleanly positive.
Medpace Holdings, Inc.
PTC Therapeutics, Inc.
The Algovestiq AIQ Score currently favors MEDP over PTCT, 57 versus 54 as of Oct 21, 2026. MEDP's advantage is driven primarily by stronger momentum and risk resilience, while PTCT holds the stronger value profile. MEDP also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors PTCT. 3 of 6 covered evidence groups favor MEDP today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. MEDP lead: Weakening — the AIQ differential moved from 9 to 3 points over 30 sessions.
Compare Medpace Holdings, Inc. and PTC Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare MEDP and PTCT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum62 vs 37MEDP +25
- Value30 vs 38PTCT +8
- Risk Resilience59 vs 55MEDP +4
- Quality79 vs 82Even
3 of 6 evidence groups favor MEDP. MEDP’s edge is concentrated in momentum and risk resilience; PTCT keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-10-20, compared against the prior scored session 2026-10-19.
No factor moved materially.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Momentum +5
New signals
- MACD Bullish Crossover — bullish, momentum, short horizon
MEDP's lead narrowed by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — MEDP and PTCT both carry a full feed there.
The central trade-off
MEDP (Medpace Holdings, Inc.): the stronger current systematic profile, led by momentum and risk resilience.
PTCT (PTC Therapeutics, Inc.): the counter-case, on value, valuation, analyst expectations — but at materially higher volatility, 42.9% against 27.9%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
MEDPMEDP on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PTCTPTCT on combined revenue and EPS growth.
Value
PTCTPTCT on the peer-relative Value factor, by 8 points.
Momentum
MEDPMEDP on the Momentum factor, by 25 points.
Lower downside
MEDPMEDP on Risk Resilience, by 4 points.
Analyst upside
PTCTPTCT on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors MEDP, analyst targets favor PTCT. That disagreement is the most useful thing on this page.
| Measure | MEDP | PTCT | Note |
|---|---|---|---|
| Implied upside to target | -13% | +64.4% | PTCT has more room |
| Target dispersion | +52.1% | +60.2% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 9 | 8 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor MEDP. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 57 vs 54 |
| Fundamentals | MEDPon balance | TTM ROE 110.1% vs 21.7%; gross margin 28.8% vs 82.1%; operating margin 21% vs 11.5% — MEDP takes 2 of 3 decided legs, not all of them |
| Valuation | PTCT | Value 30 vs 38 |
| Technicals | MEDP | Price vs 50-day 9.1% vs -6.6%; vs 200-day 18.2% vs -11.7% |
| Risk Resilience | MEDP | Risk Resilience 59 vs 55 |
| Analyst expectations | PTCT | Target upside -13% vs 64.4% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of MEDP and PTCT and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MEDP.
How the comparison changed
120 daily snapshots · Jun 21 – Oct 20MEDP lead: Weakening — the AIQ differential moved from 9 to 3 points over 30 sessions.
- Today
- MEDP +3
- 57 vs 54
- 7 sessions ago
- MEDP +4
- 58 vs 54
- 30 sessions ago
- MEDP +9
- 62 vs 53
- 90 sessions ago
- MEDP +2
- 56 vs 54
The lead changed hands 6 times in this window, most recently on Oct 12 when MEDP moved ahead of PTCT.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 0 bearish
Only MEDP
- Golden Cross Active — bullish, trend, long horizon (15.31%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
1 bullish / 2 bearish / 2 neutral, conflicted
Only PTCT
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Death Cross Active — bearish, trend, long horizon (6.34%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.51%)
- Downtrend Structure Active — bearish, trend, long horizon
Both carry 1 more signal that do not separate them: MACD Bullish Crossover.
PTCT is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +6.43%, AIQ 0 points).
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.48%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PTCT closes the Momentum gap — currently 25 points behind, the largest single contributor to MEDP's edge.
- 2PTCT's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3MEDP's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4The narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 3-point move would eliminate MEDP's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
MEDP leads on balance| Metric | MEDP | PTCT |
|---|---|---|
| Revenue growth (YoY) | 0.1% | 32.3% |
| EPS growth (YoY) | -0.9% | 34.7% |
| Gross margin | 28.8% | 82.1% |
| Operating margin | 21% | 11.5% |
| Return on equity (TTM) | 110.1% | 21.7% |
| Debt to equity | 0.28 | -4.21 |
Performance
MEDP leads 5 of 6 windows| Metric | MEDP | PTCT |
|---|---|---|
| 1 week (5 sessions) | 2.1% | 5% |
| 1 month (20 sessions) | -1.2% | -4.6% |
| 3 months (63 sessions) | 17.9% | -19.7% |
| 6 months (126 sessions) | 20.9% | -10.9% |
| Year to date | 10.8% | -17.2% |
| 1 year (252 sessions) | 19.4% | -5.8% |
Technicals
MEDP has the stronger structure| Metric | MEDP | PTCT |
|---|---|---|
| RSI (14) | 49.3 | 44.4 |
| ADX (14) | 25.5 | 18.3 |
| Price vs 50-day | 9.1% | -6.6% |
| Price vs 200-day | 18.2% | -11.7% |
| Volatility (1M, annualized) | 27.9% | 42.9% |
Risk
MEDP is the more resilient| Metric | MEDP | PTCT |
|---|---|---|
| Beta | 0.63 | 0.74 |
| Sharpe ratio | 0.52 | -0.01 |
| Sortino ratio | 0.54 | -0.01 |
| Max drawdown | -36.6% | -33.9% |
| Current drawdown | -1.2% | -29.7% |
| Annualized volatility | 44.2% | 40.8% |
| Value at risk (95%) | -3.1% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, MEDP or PTCT?
On the Algovestiq AIQ Score, MEDP is the stronger of the two as of Oct 21, 2026, scoring 57 against PTCT's 54. The edge comes from momentum and risk resilience. PTCT is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is MEDP or PTCT the better buy right now?
MEDP carries the stronger systematic profile as of Oct 21, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.
Why does the AIQ Score favor MEDP over PTCT?
The composite weights Quality, Value, Momentum and Risk Resilience. MEDP leads Momentum by 25 points; PTCT leads Value by 8 points; MEDP leads Risk Resilience by 4 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, MEDP or PTCT?
Analyst price targets imply -13% upside for MEDP and +64.4% for PTCT, so the Street currently favors PTCT. That points the opposite way to the AIQ Score, which favors MEDP. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, MEDP or PTCT?
PTCT is the better-valued of the two on the peer-relative Value factor. PTCT on the peer-relative Value factor, by 8 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, MEDP or PTCT?
PTCT on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, MEDP or PTCT?
MEDP on the Momentum factor, by 25 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, MEDP or PTCT?
MEDP is the more resilient of the two, so the other name carries the higher downside risk. MEDP on Risk Resilience, by 4 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is MEDP more profitable than PTCT?
The profitability evidence is mixed: gross margin 28.8% vs 82.1%; operating margin 21% vs 11.5%; ttm roe 110.1% vs 21.7%. MEDP leads on two measures and PTCT on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is MEDP's lead over PTCT getting stronger or weaker?
MEDP lead: Weakening — the AIQ differential moved from 9 to 3 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-21 and 2026-10-20. The lead has changed hands 6 times in that window, most recently on 2026-10-12, when MEDP moved ahead of PTCT.
What would change the MEDP vs PTCT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PTCT closes the Momentum gap — currently 25 points behind, the largest single contributor to MEDP's edge; PTCT's Death Cross Active resolves — a bearish trend rule currently active against it; MEDP's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 3-point move would eliminate MEDP's advantage entirely.
What do the current signals say about MEDP and PTCT?
MEDP: 4 bullish / 0 bearish. PTCT: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MEDP is Golden Cross Active (bullish, long horizon). On PTCT it is Death Cross Active (bearish, long horizon).
Compare MEDP and PTCT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.